Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAshley HernandezCOChristian OkitondoGMGregory A. Maglinte

Discussion

Loading...

Member takes

Overview

Observational analysis shows effective treatment continuity in CLL patients switched to zanubrutinib, suggesting minimal adverse events post-ibrutinib or acalabrutinib.

Key Points

  • Most patients switched to zanubrutinib continued treatment, with only 40% discontinuing.
  • The primary cause for prior BTKi discontinuation was treatment-related adverse events in 68.5% of patients.
  • Clinical characteristics revealed that 72% of patients had an ECOG status of 0-1 at treatment initiation.
  • Real-world evidence indicates zanubrutinib is well-tolerated and effective after switching therapies.

Cite This Study

Hernandez et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4ffhttps://doi.org/10.1182/blood-2025-8062
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy2025 · 1 citations
  2. 2Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis2025
  3. 3Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  4. 4Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting2025
  5. 5Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL2025